RTP Mobile Logo
Proceedings from the 9th Annual Winter Lung Cancer Conference, 2012
Released May 2012

Proceedings from a live event featuring traditional didactic faculty presentations and case-based panel discussions focused on all factors that influence multidisciplinary treatment decision-making for lung cancer. Featuring perspectives from Drs Chandra P Belani, Walter J Curran Jr, John Heymach, David Jablons, Pasi A Jänne, Mark G Kris, Rogerio C Lilenbaum, Thomas J Lynch Jr, Suresh Ramalingam, Alan B Sandler, Mark A Socinski and Heather Wakelee. (Video Program)

CE Disclosures and Faculty Information


    This activity has been designed to meet the educational needs of medical oncologists and other healthcare providers involved in the treatment of lung cancer.


    Lung cancer is a devastating disease that accounts for more cancer-related deaths among both men and women than any other tumor type. Historically, systemic therapeutic options have been limited, but recent advances in our understanding of cellular and tumor biology have resulted in the development of numerous therapies demonstrating benefit in lung cancer. Despite these advances, many clinical scenarios continue to exist in which multiple treatment options may be available but the optimal strategy is highly debatable and may depend on rapidly evolving clinical research data. This unique educational activity delivers highly applicable current clinical information delving into the personalized management of this challenging disease and provides clinicians with a concise, easy-to-understand resource to facilitate knowledge and application of optimal diagnostic and therapeutic approaches.


    • Develop an evidence-based strategy for the initial diagnosis and treatment of localized non-small cell lung cancer (NSCLC), exploring the role of adjuvant systemic therapy.
    • Apply the results of emerging clinical research to the recommendation of multimodality therapy for patients with Stage III NSCLC.
    • Compare and contrast the benefits and risks of combination chemobiologic and doublet and single-agent chemotherapy regimens when developing treatment plans for patients with advanced disease.
    • Use biomarkers, clinical characteristics and tumor histology to select individualized front-line and subsequent treatment approaches for patients with metastatic NSCLC.
    • Identify patients with metastatic NSCLC who may experience clinical benefit from the addition of continuation or switch maintenance biologic therapy and/or chemotherapy.
    • Select appropriate prophylactic and/or acute clinical management strategies to reduce or ameliorate toxicities associated with inhibitors of angiogenesis and EGFR.
    • Differentiate among existing and emerging molecular-targeted therapies, and effectively integrate new compounds, when available, into individualized NSCLC treatment strategies.
    • Recognize the effect of NSCLC tumor-specific mutations on relative response or resistance to treatment with EGFR tyrosine kinase inhibitors, monoclonal antibodies and other emerging molecular-targeted agents.
    • Formulate management strategies for limited- or extensive-stage small cell lung cancer, considering the contributory roles of surgery, radiation therapy (local and prophylactic cranial irradiation) and chemotherapy.
    • Recall the design of ongoing clinical trials evaluating novel investigational agents in lung cancer, and counsel appropriately selected patients about availability and participation.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


    Research To Practice designates this enduring material for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/WLCC2012/CME.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Chandra P Belani, MD
    Miriam Beckner Distinguished Professor of Medicine
    Penn State College of Medicine
    Deputy Director, Penn State Hershey Cancer Institute
    Hershey, Pennsylvania

    Advisory Committee: Genentech BioOncology, Lilly USA LLC, Pfizer Inc; Consulting Agreements: Genentech BioOncology, Lilly USA LLC.

    Walter J Curran Jr, MD

    Executive Director
    Winship Cancer Institute
    Lawrence W Davis Professor and Chair
    Department of Radiation Oncology
    Emory University
    Atlanta, Georgia

    Advisory Committee: Bristol-Myers Squibb Company; Consulting Agreement: Lilly USA LLC.

    John Heymach, MD, PhD
    Associate Professor of Thoracic/Head and Neck Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc; Paid Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, GlaxoSmithKline.

    David Jablons, MD
    Professor and Chief
    Division of General Thoracic Surgery
    Ada Distinguished Professor and Program Leader
    Thoracic Oncology
    UCSF Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco
    San Francisco, California

    Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Lilly USA LLC, OSI Oncology; Stock Ownership: Pinpoint Genomics.

    Pasi A Jänne, MD, PhD
    Director, Translational Research Laboratory
    Lowe Center for Thoracic Oncology
    Dana-Farber Cancer Institute
    Associate Professor of Medicine
    Harvard Medical School
    Co-Scientific Director
    Belfer Institute for Applied Cancer Sciences
    Boston, Massachusetts

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc; Royalties: Genzyme Corporation.

    Mark G Kris, MD

    Chief, Thoracic Oncology Service
    Attending Physician
    The William and Joy Ruane Chair in Thoracic Oncology
    Memorial Sloan-Kettering Cancer Center
    Professor of Medicine
    Weill Cornell Medical College
    New York, New York

    Advisory Committee: Pfizer Inc; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Pfizer Inc; Lecture: Roche Laboratories Inc.

    Rogerio C Lilenbaum, MD
    Chairman, Cancer Institute, Cleveland Clinic Florida
    Weston, Florida
    Professor of Medicine, Voluntary Faculty
    University of Miami School of Medicine
    Miami, Florida

    Consulting Agreements: Celgene Corporation, Genentech BioOncology.

    Thomas J Lynch Jr, MD
    Jonathan and Richard Sackler Professor of Internal Medicine
    Director, Yale Cancer Center
    Physician-in-Chief, Smilow Cancer Hospital at Yale New Haven
    New Haven, Connecticut

    Advisory Committee and Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Merck and Company Inc, SuperGen Inc; Board of Directors and Stock Ownership: Infinity Pharmaceuticals Inc.

    Suresh Ramalingam, MD
    Associate Professor of Hematology and Medical Oncology
    Director, Division of Medical Oncology
    Chief of Thoracic Oncology
    Emory University School of Medicine
    Winship Cancer Institute
    Atlanta, Georgia

    Consulting Agreement: Genentech BioOncology.

    Alan B Sandler, MD

    Professor of Medicine
    Division Chief, Hematology and Medical Oncology
    DeArmond Chair for Clinical Cancer Research
    Co-Director, Clinical Management Research
    Associate Director for Clinical Research
    Knight Cancer Institute
    Oregon Health and Science University
    Portland, Oregon

    Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Roche Laboratories Inc; Consulting Agreements: Allos Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Roche Laboratories Inc; Paid Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Pfizer Inc; Speakers Bureau: Genentech BioOncology, Lilly USA LLC.

    Mark A Socinski, MD

    Professor of Medicine and Thoracic Surgery
    Director, Lung Cancer Section
    Division of Hematology/Oncology
    Co-Director, UPMC Lung Cancer Center of Excellence
    Co-Director, Lung and Thoracic Malignancies Program
    University of Pittsburgh
    UPMC Cancer Pavilion
    Pittsburgh, Pennsylvania

    Paid Research: Celgene Corporation, Genentech BioOncology, Lilly USA LLC, Pfizer Inc, Synta Pharmaceuticals Corp; Speakers Bureau: Genentech BioOncology, Lilly USA LLC.

    Heather Wakelee, MD
    Assistant Professor of Medicine
    Division of Oncology
    Stanford University School of Medicine
    Stanford Cancer Institute
    Stanford, California

    No real or apparent conflicts of interest to disclose.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Abbott Laboratories, ArQule Inc, Astellas, Biodesix Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Lilly USA LLC and Teva.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: May 2012
    Expiration date: May 2013

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):